Clinical Trial

A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCI

Study acronym: RISE
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2024 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, randomized, placebo-double-blind, multicenter clinical trial. The purpose of this study is to investigate whether "butylphthalide +PCI" combined treatment mode on the basis of traditional drug therapy could reduce myocardial infarct size, improve cardiac function and long-term prognosis of patients with acute myocardial infarction, and verify the drug safety of butylphthalide in the treatment of STEMI within the window period of 12 hours.
Trial Details
NCT Number NCT06704685
Lead Sponsor Xiangya Hospital of Central South University
Collaborators: CSPC Pharmaceutical Group Limited
Conditions ST-segment Elevation Myocardial Infarction (STEMI)
Enrollment 40 participants
Start Date 2024-12-01
Primary Completion 2025-10-01 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-26